158 related articles for article (PubMed ID: 10568575)
21. Efficacy and safety of a combined rituximab chemotherapy during pregnancy.
Herold M; Schnohr S; Bittrich H
J Clin Oncol; 2001 Jul; 19(14):3439. PubMed ID: 11454895
[No Abstract] [Full Text] [Related]
22. CD20 positive childhood B-non Hodgkin lymphoma (B-NHL): morphology, immunophenotype and a novel treatment approach: a single center experience.
Bilić E; Femenić R; Konja J; Simat M; Dubravcić K; Batinić D; Ries S; Rajić L
Coll Antropol; 2010 Mar; 34(1):171-5. PubMed ID: 20432747
[TBL] [Abstract][Full Text] [Related]
23. A complete response with rituximab in metastatic diffuse large B-cell lymphoma of the testis: case report.
Autorino R; Lamendola MG; De Sio M; Di Trolio RA; Ferraraccio F; Di Lorenzo G
Int J Immunopathol Pharmacol; 2007; 20(2):401-3. PubMed ID: 17624254
[TBL] [Abstract][Full Text] [Related]
24. Rituximab alone was effective for the treatment of a diffuse large B-cell lymphoma associated with hemophagocytic syndrome.
Sano T; Sakai H; Takimoto K; Ohno H
Int J Clin Oncol; 2007 Feb; 12(1):59-62. PubMed ID: 17380444
[TBL] [Abstract][Full Text] [Related]
25. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma.
Eur J Cancer Care (Engl); 2003 Dec; 12(4):306-7. PubMed ID: 14982308
[No Abstract] [Full Text] [Related]
26. CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab.
Ifthikharuddin JJ; Mieles LA; Rosenblatt JD; Ryan CK; Sahasrabudhe DM
Am J Hematol; 2000 Oct; 65(2):171-3. PubMed ID: 10996837
[TBL] [Abstract][Full Text] [Related]
27. Anti-CD20 antibody (rituximab) administration in patients with late occurring lymphomas after solid organ transplant.
Dotti G; Rambaldi A; Fiocchi R; Motta T; Torre G; Viero P; Gridelli B; Barbui T
Haematologica; 2001 Jun; 86(6):618-23. PubMed ID: 11418370
[TBL] [Abstract][Full Text] [Related]
28. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Griffin TC; Weitzman S; Weinstein H; Chang M; Cairo M; Hutchison R; Shiramizu B; Wiley J; Woods D; Barnich M; Gross TG;
Pediatr Blood Cancer; 2009 Feb; 52(2):177-81. PubMed ID: 18816698
[TBL] [Abstract][Full Text] [Related]
29. Rituximab in diffuse large B-cell lymphoma.
Coiffier B
Clin Adv Hematol Oncol; 2004 Mar; 2(3):156-7. PubMed ID: 16166943
[No Abstract] [Full Text] [Related]
30. Fulminant hepatitis B following rituximab therapy in a patient with Evans syndrome and large B-cell lymphoma.
Ozgönenel B; Moonka D; Savaşan S
Am J Hematol; 2006 Apr; 81(4):302. PubMed ID: 16550511
[No Abstract] [Full Text] [Related]
31. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
32. Thalidomide induced remission of refractory diffuse large B-Cell Lymphoma post-allogeneic SCT.
Tueger S; Chen FE; Ahsan G; McDonald V; Andrews VE; Madrigal JA; Kazmi MA
Haematologica; 2006 Jun; 91(6 Suppl):ECR16. PubMed ID: 16785122
[TBL] [Abstract][Full Text] [Related]
33. Rituximab for early-stage diffuse large-B-cell lymphoma.
Friedberg JW
Lancet Oncol; 2006 May; 7(5):357-9. PubMed ID: 16648037
[No Abstract] [Full Text] [Related]
34. Rituximab for bone lymphoma.
Savage DG; Staron R
Ann Intern Med; 2001 Jun; 134(12):1156-7. PubMed ID: 11412072
[No Abstract] [Full Text] [Related]
35. Intrathecal rituximab treatment for pediatric post-transplant lymphoproliferative disorder of the central nervous system.
van de Glind G; de Graaf S; Klein C; Cornelissen M; Maecker B; Loeffen J
Pediatr Blood Cancer; 2008 Apr; 50(4):886-8. PubMed ID: 17668865
[TBL] [Abstract][Full Text] [Related]
36. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
[TBL] [Abstract][Full Text] [Related]
37. Does rituximab really induce hepatitis C virus reactivation?
Ennishi D; Yokoyama M; Terui Y; Takeuchi K; Ikeda K; Tanimoto M; Hatake K
J Clin Oncol; 2008 Oct; 26(28):4695-6; author reply 4696. PubMed ID: 18824720
[No Abstract] [Full Text] [Related]
38. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma.
Racila E; Link BK; Weng WK; Witzig TE; Ansell S; Maurer MJ; Huang J; Dahle C; Halwani A; Levy R; Weiner GJ
Clin Cancer Res; 2008 Oct; 14(20):6697-703. PubMed ID: 18927313
[TBL] [Abstract][Full Text] [Related]
39. Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remission.
Knoop C; Kentos A; Remmelink M; Garbar C; Goldman S; Feremans W; Estenne M
Clin Transplant; 2006; 20(2):179-87. PubMed ID: 16640524
[TBL] [Abstract][Full Text] [Related]
40. Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy.
van der Kolk LE; Grillo-López AJ; Baars JW; van Oers MH
Leukemia; 2003 Aug; 17(8):1658-64. PubMed ID: 12886256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
